QT prolongation predicts short-term mortality independent of comorbidity.

AIMS: A prolonged corrected QT interval (QTc) ≥500 ms is associated with high all-cause mortality in hospitalized patients. We aimed to explore any difference in short- and long-term mortality in patients with QTc ≥500 ms compared with patients with QTc <500 ms after adjustment for comorbidity and main diagnosis. METHODS AND RESULTS: Patients with QTc ≥500 ms who were hospitalized at Telemark Hospital Trust, Norway between January 2007 and April 2014 were identified. Thirty-day and 3-year all-cause mortality in 980 patients with QTc ≥500 ms were compared with 980 patients with QTc <500 ms, matched for age and sex and adjusting for Charlson comorbidity index (CCI), previous admissions, and main diagnoses. QTc ≥500 ms was associated with increased 30-day all-cause mortality [hazard ratio (HR) 1.90, 95% confidence interval (CI) 1.38-2.62; P < 0.001]. There was no significant difference in mortality between patients with QTc ≥500 ms and patients with QTc <500 ms who died between 30 days and 3 years; 32% vs. 29%, P = 0.20. Graded CCI was associated with increased 3-year all-cause mortality (CCI 1-2: HR 1.62, 95% CI 1.34-1.96; P < 0.001; CCI 3-4: HR 2.50, 95% CI 1.95-3.21; P < 0.001; CCI ≥5: HR 3.76, 95% CI 2.85-4.96; P < 0.001) but was not associated with 30-day all-cause mortality. CONCLUSION: QTc ≥500 ms is a powerful predictor of short-term mortality overruling comorbidities. QTc ≥500 ms also predicted long-term mortality, but this effect was mainly caused by the increased short-term mortality. For long-term mortality, comorbidity was more important.

Genetic and Phenotypic Characterization of Community Hospital Patients With QT Prolongation.

Background Congenital long- QT syndrome ( LQTS ) is a genetic disorder characterized by prolongation of the corrected QT interval ( QT c) on an ECG . The aim of the present study was to estimate the prevalence of pathogenic and likely pathogenic sequence variants in patients who had at least 1 ECG with a QT c ≥500 ms. Methods and Results Telemark Hospital Trust is a community hospital within the Norwegian national health system, serving ≈173 000 inhabitants. We searched the ECG database at Telemark Hospital Trust, Norway, from January 2004 to December 2014, and identified 1531 patients with at least 1 ECG with a QT c ≥500 ms. At the time of inclusion in this study (2015), 766 patients were alive. A total of 733 patients were invited to participate, and 475 accepted. The 17 genes that have been reported to cause monogenic LQTS were sequenced among the patients. Pro- QT c score was calculated for each patient. A molecular genetic cause of LQTS was detected in 31 (6.5%) of 475 patients. These patients had a lower pro- QT c score than those without pathogenic or likely pathogenic variants (1.7±1.0 versus 2.8±1.6; P<0.001). Conclusions Compared with the general population, hospitalized patients with a QT c ≥500 ms in at least 1 ECG recording had an increased likelihood for pathogenic and likely pathogenic variants in LQTS genes. We recommend increased awareness of the possibility of LQTS in patients with at least 1 ECG with a QT c ≥500 ms.

Predictors of mortality in high-risk patients with QT prolongation in a community hospital.

Aims: To determine predictors of mortality in patients with corrected QT interval (QTc) ≥ 500 ms in a community hospital. Methods and results: In this retrospective observational study, we searched the electrocardiogram (ECG) database at Telemark Hospital Trust, Norway, from January 2004 to December 2014. Medication, electrolyte abnormalities, and medical conditions known to prolong the QT interval were recorded. From the medical records, we assessed whether the prolonged QTc was noted by the health care providers. We identified 1531 patients (age = 70 ± 15 years, 59% female) with an ECG with QTc ≥ 500 ms. All-cause mortality during 952 (range 0-4161) days of follow-up was 50% (n = 765/1531). Main predictors of mortality were aborted cardiac arrest [hazard ratio (HR) 2.40, 95% confidence interval (CI) 1.44-4.01; P = 0.001], cerebral stroke/head trauma (HR 2.28, 95% CI 1.70-3.05; P < 0.001), and heart failure (HR 1.74, 95% CI 1.43-2.12; P< 0.001). Females with prolonged QTc had better survival compared with males (P = 0.006). We constructed a risk-weighted QTc mortality score. QT prolongation was acknowledged in the medical records in 12% of the cases. Conclusions: QTc ≥ 500 ms was associated with high all-cause mortality with increased mortality in males compared with females. A new QTc mortality score was constructed to predict mortality. Only a minority of cases with prolonged QTc ≥ 500 ms were acknowledged in the medical records.

Cardiotoxic effects of trastuzumab.

BACKGROUND: Breast cancer with overexpression of the HER2 receptor is an aggressive type of breast cancer with poor prognosis. Trastuzumab (Herceptin) is a monoclonal antibody that binds to the HER2 receptor on the cell surface blocking the signals that promote cell-growth proliferation. Trastuzumab treatment has almost halved the risk of relapse, when given as an adjuvant, and has improved the overall survival in metastatic breast cancer. However, when given alone or in combination with cardiotoxic chemotherapy, especially anthracyclines, trastuzumab may lead to congestive heart failure of varying severity. MATERIAL AND METHODS: The article is a non-systematic review of articles from clinical trails, basic research, and recommendations by Norwegian and international expert panels. RESULTS: The cardiotoxic effects of trastuzumab and anthracycline in combination were already reported in the pivotal trials. Over ten years of research have revealed the mechanisms of cardiotoxicity with trastuzumab. Risk factors have been identified and recommendations drawn up for cardiac surveillance and treatment of patients with signs of heart failure. By following these recommendations the incidence of heart failure is reduced to approximately five per cent of treated patients. CONCLUSION: In summary, the favourable effects of trastuzumab are convincing, but cardiotoxicity is a significant challenge in treatment. Risk factors for side effects indicate extra vigilance, but the side effects are unpredictable and all patients treated with trastuzumab must undergo regular cardiac surveillance.

[Simple electrophysiologic examination of patients with palpitation or tachycardia]. / Forenklet elektrofysiologisk undersøkelse ved hjertebankanfall.

BACKGROUND: Discomfort because of palpitation and tachycardia is a frequent phenomenon. Clinical practice for diagnosing tachycardia has a low sensitivity, and patients without a correct diagnosis are often not treated optimally. MATERIAL AND METHODS: Results from all 24-hour-ECGs taken at Telemark Hospital in the period 1.8.04-31.7.05 were reviewed. Indications and findings were retrieved from the hospital database. 252 of totally 614 ECGs were performed for the indications palpitation and tachycardia. 137 patients with an unclear diagnosis were offered a simple electrophysiologic examination with stimulation of the right atrium by a pacemaker electrode. 38 of these patients were included and underwent the examination. An additional 18 patients were referred to a simple electrophysiologic examination based on the same criteria. RESULTS: 24-hour-ECG provided a diagnosis for 29 patients with palpitation and tachycardia. A simple electrophysiologic examination uncovered reentry tachycardia in nine patients and paroxystic atrial flutter in three patients. A total of 56 electrophysiologic examinations were performed, uncovering 12 cases of tachycardia suitable for ablation. Two patients had to undergo DC-conversion, no other complication was observed. INTERPRETATION: A simplified electrophysiologic examination of this group of patients will uncover tachycardia suitable for ablation in approximately 20 % of the patients, and increase diagnostic yield of supraventricular tachycardia by 64 %.

[Stroke--a study of clinical management and prognosis]. / Hjerneslag--en studie av klinisk håndtering og forløp.

BACKGROUND: Knowledge on how to treat stroke effectively is increasing, but is not always implemented into clinical practice. The aim of this study was to establish the treatment offered, clinical status at discharge and long-term results for stroke patients admitted to a Norwegian local hospital. MATERIAL AND METHODS: 421 patients were treated for stroke at Baerum hospital during the years 1994-1995. Patient history, medication, radiological findings and clinical findings at admission and discharge were recorded in a local register. Data on survival and re-hospitalisation for recurrent stroke were recorded for a period 7 to 9 years after discharge, i.e. until January 2003. RESULTS: Hospital mortality was 17%. 49% were discharged directly to their homes. No antihypertensive treatment was given to 106 (51.6%) of the 206 patients who had hypertension upon discharge. 273 (90%) of the 303 patients discharged after cerebral infarction, were receiving antithrombotic treatment with warfarin or acetylic salicylic acid upon discharge. The most important prognostic factor for survival and functional ability was the patient's age at the time of stroke and next, the stroke's anatomical localization and extent. INTERPRETATION: Registers for follow-up of stroke patients provide valuable information on clinical practice and can form a basis for improved treatment of stroke in the future.